Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Misonix Inc. (MSON) -- Ignore unavailable to you. Want to Upgrade?

To: Candle stick who wrote (632)	1/28/1998 9:25:00 AM
From: Wesley0428	Respond to of 947

Overall excellent report. $.14 vs. Flomenhaft estimate of $.10 and my estimate of $.12. Better yet on an "apples to apples" fully taxed equivalent basis, which is the way the Street looks at these things. In other words if we look at this year and last year as though the tax rate was 40% in both years (my estimate of the ultimate full tax rate for Misonix), they did $.12 for Q2'98 vs $.07 for Q2'97. That's a 71% increase, slightly exceeding revenue growth. Revenue blew away estimates. Continued healthy core business growth, less fall-off in Lysonix revenues than I had projected, and a faster ramp up of USS sales than expected. Gross margins were a bit disappointing to me. I knew they would be down as the USS product has lower margins, but they were off more than I expected (this is due in part to the fact that USS revenues were a bigger piece of the pie than I expected). SG&A was up significantly. I'll try to find out why. R&D was down significantly. Seems to fluctuate wildly based on licensing deal income. To put UAL business history in perspective, despite Lysonix "inventory" problem, UAL revenues were up over 70% from last year's Q2. Most companies would be crowing about that, not apologizing. This stock should go to at least $10 once the Mentor injunction is history. I give us a 90% chance of winning that battle. That's an "expected value" of $9, or a 50% gain from yesterday's prices. Not a bad wager. Fundamentally speaking, on a fully taxed basis, the trailing twelve month actual earnings are $.60. That gives us a ttm P/E of 10X. On the same basis, earning YTD are up 77% over last year. That's a (loosly interpreted) PEG of .13. Generally anything with a PEG less than .5 is considered extremely undervalued.

To: Candle stick who wrote (632)	1/28/1998 9:33:00 AM
From: Candle stick	Read Replies (1) \| Respond to of 947

This looks like a great report, read the part below: Dr. Joseph Librizzi, President and Chief Executive Officer, said, ''We are pleased with the strong growth in the Company's revenue and earnings this quarter. While much of this growth came from our medical products division where we had a 248% increase in revenue, we also experienced significant increases in our core scientific and industrial products division, where revenues were 20% ahead of last year. Approximately half of the medical products growth came from our exclusive agreement with United States Surgical Corporation (NYSE: USS - news), as shipments to USS began in November 1997.'' Dr. Librizzi added, ''Our relationship with U.S. Surgical is ahead of plan, having reached several milestones relating to our exclusive license agreement. During the quarter we began shipments of ultrasonic generators and transducers, which are the main components of USS's AutoSonix(a) ultrasonic cutting system. We also received an initial order for the manufacture of probes to be used with AutoSonix(a), as well as a follow-up order for ultrasonic generators and transducers.'' Looks like MSON is firing on all cylinders.........;^)